Last reviewed · How we verify
Raptiva
At a glance
| Generic name | Raptiva |
|---|---|
| Also known as | efalizumab, anti-CD11a monoclonal antibody, Efalizumab |
| Sponsor | National Institute of Dental and Craniofacial Research (NIDCR) |
| Target | Leukocyte adhesion glycoprotein LFA-1 alpha |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | discontinued |
Approved indications
- Plaque psoriasis
Common side effects
Key clinical trials
- Ex Vivo Monocyte and Lymphocyte Stimulation Tests and Genomic Study for the Prediction of Efficacy and Adverse Effects of CD11a Monoclonal Antibodies(Raptiva) (N/A)
- Development of Immunosuppression Regimens to Facilitate Single Donor Islet Transplantation Using Abatacept (Phase 2)
- Efalizumab in the Treatment of Alopecia Totalis/Universalis in Young Adults, Phase II (Phase 2)
- A Phase IV Multicentre, Randomized Double-blind, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Raptiva in the Treatment of Subjects With Moderate to Severe Chronic Plaque Psoriasis I (Phase 4)
- An Open-Label Study to Determine Equivalence in Efficacy, Organ Safety and Systemic Tolerability Between Infliximab in GROUP I ("High Need") and GROUP II ("Low Need") Patients Suffering From Chronic P (Phase 3)
- A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis (Phase 4)
- A Phase IV Multicentre, Randomised, Double-blind, Placebo Controlled, Trial to Evaluate the Safety and Efficacy of Raptiva ® in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis Invol (Phase 4)
- A Phase IIIb, Open-Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis, Including Those Who Are Recei (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Raptiva CI brief — competitive landscape report
- Raptiva updates RSS · CI watch RSS
- National Institute of Dental and Craniofacial Research (NIDCR) portfolio CI